About this trial
The goal of this observational study is to compare swept source optical coherence tomography devices ability to detect macular neovascularisation when there is a large pigment epithelium detachment higher than 250 microns
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients treated for neovascular age related macular degeneration (AMD)
Presence of a pigmentary epithelium detachment higher than 250 microns measured on structural optical coherence tomography (OCT)
Disqualifiers
Poor image quality or signal strength
Undefined retina layers
Trial population
Patients treated for neovascular age related macular degeneration (AMD)
Trial design
Cohort
Prospective
Treatments tested in this trial
Optical Coherence Tomography Angiography (OCT-A)
Diagnostic testTwo Optical Coherence Tomography Angiography swept source devices are compared for the detection of large pigment epithelium detachments in age related macular degeneration. The sensitivity of the devices is compared in both the automatic segmentation done by the device and the manual segmentation done by a retina specialist.
Treatment groups
Trial outcomes
Primary outcomes
Sensitivity of the detection of neovascularisation in large pigment epithelium detachment by swept source optical coherence tomography devices
The optical coherence tomography angiography devices are known to have a difficult time detecting neovascularisation in the cases of large pigment epithelium detachments (PED), because of the many layers and the distance the OCT signal has to cross. The automatic retina segmentation (done by the device of the different retina layers plays a big role in this detection. It's also disturbed by the height of the PED. This study aims to compare the sensitivity of two swept source OCT devices available in the market : Bmizar, Towardpi and Plexelite, Zeiss. After the exam image acquisition, a retina specialist will try to make a manual segmentation of the retina analysed to help the detection of macular neovascularisation that would have been missed in the "normal" automatic segmentation done by the device.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: